It’s natural to wonder if now is the right moment to consider investing in Cidara Therapeutics, Inc. (CDTX). We’re going to break down its performance in the current market, giving you all the insights you need. Let’s explore whether CDTX stock is poised for a breakout or if there are underlying currents you should be aware of.
Here’s What You Need to Know Right Now About CDTX Stock
As of November 2025, CDTX stock is trading at $219.02. What’s exciting is that it’s showing some strong positive momentum, comfortably positioned above both its 50-day and 200-day moving averages. This often signals a healthy uptrend.
However, it’s a nuanced picture. While analysts are generally optimistic, projecting a 1-year price target of $291.09 (a potential +32.9% upside), the average analyst consensus target is a bit lower at $209.38, suggesting a slight downside from the current price. You should also be aware of the significant volatility, with an annualized rate of 313.7%. This tells us CDTX can experience wide price swings, offering both opportunities and risks.
Cidara Therapeutics, Inc.’s story is quite compelling. The company benefits from a portfolio of established brands, which is a definite plus. But like many in the biotechnology space, it faces stiff competition, a challenge it must continually navigate.
What’s Inside This Comprehensive CDTX Stock Analysis?
We’re not just here to throw numbers at you; our goal is to provide a clear, insightful breakdown of CDTX stock from every angle. This way, you can make a truly informed investment decision.
- ✅ Is now a good time to buy CDTX?
- Technicals suggest a “Neutral” stance, though the RSI is alarmingly overbought at 97.8.
- Fundamentals appear “solid,” driven by manageable debt levels and promising growth metrics.
- ✅ Can CDTX’s core operations drive future growth?
- Future growth will largely hinge on its performance within its core Biotechnology operations and its ability to effectively manage competitive pressures.
- ✅ What are the biggest risks for Cidara Therapeutics?
- The company carries $1.98 million in debt, which could become a headwind, especially in a rising interest rate environment.
- Competition in its sector is fierce, coming from both established pharmaceutical giants and innovative new entrants.
Forget the jargon-filled reports or overly simplistic “just buy it” advice. Our aim is to give you clear, actionable information, whether you’re building a long-term portfolio or looking for quicker gains. So, is Cidara Therapeutics, Inc. the right investment to help your money grow? Or are there hidden issues to be cautious about? Let’s dive into the data and uncover the full story.
Key Metrics and Forecast Summary for CDTX Stock
Let’s quickly get to the heart of Cidara Therapeutics’ current market standing with a snapshot of its vital statistics and future outlook.
| Metric Category | Metric | Value | Insight |
|---|---|---|---|
| Current Price | Live Market Price | $219.02 | As of November 2025 |
| Price Targets & Forecasts | 1-Month Forecast | $219.02 | 📈 +0.0% (Neutral short-term) |
| 1-Year Forecast | $291.09 | 📈 +32.9% (Significant potential upside) | |
| Analyst Mean Target | $209.38 | 📉 -4.4% (Slightly below current price) | |
| Trend & Momentum | Trend | 🚀 ▲ Bullish | Price > SMA 50/200, indicating strong upward momentum |
| RSI (14-day) | 97.8 | 🔥 Overbought (Suggests caution) | |
| MACD | 11.88 | 📈 Bullish Short-Term Trend | |
| Key Technical Levels | Above SMA 50 | ✅ $117.16 | Strong support level |
| Above SMA 200 | ✅ $66.22 | Long-term bullish indicator | |
| 52-Week Range | 📏 $15.22 – $219.64 | Shows significant price movement over the last year | |
| Volatility | Volatility (30d Ann.) | 313.7% | 🌪️ High volatility, expect wide price swings |
| Beta (vs. Market) | 1.55x | 🎢 High Sensitivity (Moves more than the broader market) | |
| Green Days (30d) | 19/30 (63%) | 🟢 More up days than down days recently | |
| Ownership | Institutional Ownership | 103.59% | 🏛️ Very high institutional backing |
| Short % of Float | 10.93% | 😰 High Bearish Bets (Significant short interest) |
Right now, CDTX’s stock is trading at $219.02, and the technical signals are painting a distinctly bullish picture. This is because the price is holding strong above both its 50-day (at $117.16) and 200-day (at $66.22) moving averages, suggesting a clear upward trajectory. It looks like the stock has been building significant momentum recently.
However, there’s a yellow flag: the Relative Strength Index (RSI) is currently at 97.8, which is a classic “overbought” signal. While the MACD indicator does show a bullish short-term trend, the high RSI suggests we might see some minor pullbacks before the stock continues its climb. It’s a bit like a runner who’s sprinted too fast and needs a quick breather.
Also Read – RGC Stock: The Case for Upside in 2025
Looking back over the past year, CDTX’s stock has seen a wide trading range, from $15.22 to $219.64. This tells us a couple of things: first, the stock has made an incredible recovery from its lows, and second, its current price is sitting near the top of this range. This means that while big swings are common for CDTX, a rapid move much higher might be less likely without significant new catalysts. Analysts are forecasting a robust 1-year target of $291.09 (+32.9%), though the average consensus target is a more conservative $209.38 (-4.4%). Interestingly, the institutional ownership stands at a very high 103.59%, yet there’s still notable short interest at 10.93%, indicating a segment of investors are betting on a price decline.
Price Forecast Chart: CDTX’s Potential Path
While we can’t show you the visual chart here, imagine a line tracking CDTX’s recent average prices, then branching out into a forecasted range. This chart typically displays the low, average, and high price projections based on an advanced Prophet model. It gives us a visual sense of where the stock might be headed.
Detailed CDTX Price Forecast Table
Let’s get into the specifics of what the model is predicting for Cidara Therapeutics (CDTX) over the coming months. The overall projected range for CDTX is quite broad, from approximately $128.70 to $331.77 over the next year.
What’s interesting is that while the forecast range starts narrow, it widens over time, implying a relatively consistent level of forecast uncertainty. This means the model isn’t suggesting a sudden drop in confidence, but rather the natural expansion of possibilities as we look further into the future.
| Month (Period) | Min. Price | Avg. Price | Max. Price | Potential ROI vs Current ($219.02) | Model Signal |
|---|---|---|---|---|---|
| 2025-11 | $219.02 | $219.02 | $219.02 | ● 0.0% | Hold/Neutral |
| 2025-12 | $128.70 | $154.53 | $187.54 | ▼ -29.4% | Consider Short |
| 2026-01 | $152.32 | $175.75 | $200.76 | ▼ -19.8% | Consider Short |
| 2026-02 | $145.23 | $167.54 | $191.39 | ▼ -23.5% | Consider Short |
| 2026-03 | $130.46 | $155.82 | $179.65 | ▼ -28.9% | Consider Short |
| 2026-04 | $139.89 | $161.82 | $192.87 | ▼ -26.1% | Consider Short |
| 2026-05 | $157.98 | $189.36 | $217.10 | ▼ -13.5% | Consider Short |
| 2026-06 | $170.25 | $199.39 | $228.07 | ▼ -9.0% | Consider Short |
| 2026-07 | $185.27 | $215.83 | $246.26 | ▼ -1.5% | Hold/Neutral |
| 2026-08 | $215.35 | $243.62 | $278.24 | ▲ 11.2% | Consider Buy |
| 2026-09 | $242.25 | $264.25 | $296.32 | ▲ 20.7% | Consider Buy |
| 2026-10 | $263.04 | $291.09 | $318.29 | ▲ 32.9% | Consider Buy |
| 2026-11 | $279.68 | $308.30 | $331.77 | ▲ 40.8% | Consider Buy |
It’s crucial to remember that these forecasts are based on model estimates. They are inherently uncertain and can change rapidly depending on new data and shifting market conditions. Think of them as educated guesses, not guarantees of future prices.
Cidara Therapeutics, Inc. (CDTX) Company Profile
Before diving deeper into the financials, let’s get a clear picture of what Cidara Therapeutics, Inc. (CDTX) actually does. Understanding its core business provides the essential context for our analysis.
| Category | Detail |
|---|---|
| Sector | Healthcare |
| Industry | Biotechnology |
| Market Cap | $6.89 Billion |
| Employees | 38 |
| Website | https://www.cidara.com |
Business Overview
Cidara Therapeutics, Inc. is a biotechnology company with a vital mission: developing targeted therapies for patients battling cancers and other serious diseases. They are truly at the forefront of medical innovation.
One of the company’s flagship products is rezafungin acetate. This is a novel molecule within the echinocandin class of antifungals, designed to treat and prevent invasive fungal infections. We’re talking about serious conditions like candidemia and invasive candidiasis, which unfortunately carry high mortality rates. Cidara’s work here is literally life-saving.
Beyond rezafungin, Cidara is also developing its cutting-edge Cloudbreak platform. This platform enables the creation of novel drug-Fc conjugates. A prime example is CD388, a powerful antiviral aimed at providing universal prevention and treatment for both seasonal and pandemic influenza. This promising therapy is currently progressing through Phase 1 and Phase 2a clinical trials.
Originally incorporated in 2012 as K2 Therapeutics, Inc., the company officially became Cidara Therapeutics, Inc. in July 2014. They are proudly based in San Diego, California, a hub for biotech innovation.
Total Valuation of Cidara Therapeutics (CDTX)
When we look at Cidara Therapeutics, Inc. (CDTX), its market capitalization stands at a significant $6.89 billion. However, what’s particularly noteworthy for investors is its enterprise value, which is slightly lower at $6.47 billion. This difference highlights a strong net cash position of approximately $420 million. Such financial strength provides the company with a comfortable cushion and significant flexibility for future investments and strategic moves.
The upcoming earnings report on November 6, 2025, will be a crucial event. It will offer key insights into whether Cidara Therapeutics, Inc.’s core businesses can truly grow into its current valuation. Essentially, with CDTX, you’re paying for quality and future potential – and quality rarely comes cheap.
| Metric | Value |
|---|---|
| Market Cap | $6.89 Billion |
| Enterprise Value | $6.47 Billion |
| EV/EBITDA (TTM) | -40.48x |
| Next Earnings Date | 2025-11-06 |
CDTX Share Statistics: Ownership & Short Interest
Understanding who owns a company’s shares and how many are being bet against can tell you a lot about investor sentiment. For Cidara Therapeutics (CDTX), roughly 25.8% of the company’s shares are closely held by insiders or strategic investors. This leaves about 23 million shares available for public trading, known as the “float.”
However, investors should always be mindful that a company can issue more shares, which could potentially dilute the value of existing stock. Interestingly, executives and major shareholders own a relatively small portion of the company (0.71%), which might suggest they don’t have a substantial amount of “skin in the game” if the company faces difficulties. On the flip side, the level of ownership by institutions is quite significant, coming in at an impressive 103.59%. This high institutional backing often indicates a degree of stability and confidence in the stock.
Now, let’s talk about short interest. With approximately 3 million shares shorted, representing 10.93% of the float, it suggests that a notable portion of the market is currently betting against CDTX. This indicates a high perceived risk by some investors. It’s wise to keep an eye on changes in short interest; a sharp increase could signal growing doubt, while a very low short interest during positive news might make a “short squeeze” less likely.
| Metric | Value |
|---|---|
| Shares Outstanding | 31 Million |
| Implied Shares Outstanding | 31 Million |
| Shares Float | 23 Million |
| Insider Ownership | 0.71% |
| Institutional Ownership | 103.59% |
| Shares Short | 3 Million |
| Short Ratio (Days To Cover) | 3.20x |
| Short % of Float | 10.93% |
| Shares Short (Prior Month) | 3 Million |
| Short Date | 2025-10-31 |
Valuation Metrics for CDTX Stock
When we look at Cidara Therapeutics (CDTX) through the lens of traditional valuation metrics, we see some interesting dynamics that require careful interpretation. The company’s Trailing P/E ratio is currently unavailable, which isn’t uncommon for biotech companies in certain stages of development. However, its Forward P/E stands at -28.04x. A negative P/E typically indicates that a company is expected to have negative earnings in the future, which is something investors need to consider carefully.
From an enterprise value perspective, the EV/EBITDA multiple is -40.48x. This metric aims to provide a more holistic valuation by including debt and cash. These valuation metrics, while unusual due to negative earnings, offer a comprehensive view of Cidara Therapeutics’ current market positioning and highlight that it’s an investment based more on future potential than current profitability.
| Metric | Value |
|---|---|
| Forward P/E | -28.04x |
| Price/Book (MRQ) | $15.21 |
| EV/EBITDA (TTM) | -40.48x |
CDTX Financial Health Check
A deep dive into Cidara Therapeutics’ (CDTX) financial data reveals a mix of strengths and areas that warrant attention. For instance, the company’s Return on Equity (ROE) at -68.70% and Return on Assets (ROA) at -29.35% reflect that it’s not yet highly efficient in generating returns from its capital. These kinds of figures are sometimes seen in growth-oriented biotech firms that are heavily investing in R&D rather than showing immediate profits.
However, it’s not all challenging. CDTX maintains a manageable debt load with a Debt/Equity ratio of 0.47x, balancing $1.98 million in debt against a healthy $420.02 million in cash. This strong cash position provides a significant buffer. A key concern, though, is the negative operating cash flow of -$132.94 million (TTM), indicating that the core business is currently consuming more cash than it generates.
On the liquidity front, Cidara looks quite strong. Its Current Ratio of 4.62x and Quick Ratio of 4.40x demonstrate a solid ability to cover its short-term liabilities. This means the company has ample liquid assets to meet its immediate financial obligations, which is a reassuring sign for investors.
| Metric | Value |
|---|---|
| Return on Equity (ROE TTM) | -68.70% |
| Return on Assets (ROA TTM) | -29.35% |
| Debt/Equity (MRQ) | 0.47x |
| Total Cash (MRQ) | $420.02 Million |
| Total Debt (MRQ) | $1.98 Million |
| Current Ratio (MRQ) | 4.62x |
| Quick Ratio (MRQ) | 4.40x |
| Operating Cash Flow (TTM) | -$132.94 Million |
| Levered Free Cash Flow (TTM) | -$32.15 Million |
CDTX Profitability and Growth Analysis
Delving into Cidara Therapeutics’ (CDTX) margin performance reveals that the company is currently facing significant pressure on its profitability. The gross margin, operating margin, and EBITDA margin are all reported as 0.00%. This indicates that as of the last twelve months, the company is not generating positive margins from its sales, which is typical for a biotech firm in its development phase rather than a mature, revenue-generating one.
With a Profit Margin of 0.00%, it means CDTX isn’t retaining any net profit for every dollar of revenue. This isn’t necessarily a long-term red flag for biotech, but it highlights the company’s current stage. It’s more about investing in future products.
When we look at raw earning power, CDTX reports -$159.78 million in EBITDA and -$131.82 million in gross profit. Its net income, at -$184.80 million, further underscores that the company is currently in a phase of significant investment rather than profitability. In the future, maintaining or improving these margins will be absolutely critical. CDTX will need to establish strong pricing power for its therapies and rigorously control operating costs, especially as it seeks to achieve revenue growth.
| Metric | Value |
|---|---|
| Profit Margin (TTM) | 0.00% |
| Operating Margin (TTM) | 0.00% |
| Gross Margin (TTM) | 0.00% |
| EBITDA Margin (TTM) | 0.00% |
| Revenue (TTM) | 0 |
| Gross Profit (TTM) | -$131.82 Million |
| EBITDA (TTM) | -$159.78 Million |
| Net Income (TTM) | -$184.80 Million |
CDTX Dividends and Shareholder Returns
For income-focused investors, it’s important to note that based on available data, Cidara Therapeutics (CDTX) does not currently pay a regular dividend. This isn’t uncommon for biotechnology companies, especially those in growth or development stages.
This approach suggests that the company is prioritizing reinvesting its earnings and capital back into the business. This reinvestment is typically aimed at funding research and development, expanding its pipeline, and ultimately driving future growth, which could lead to capital appreciation for shareholders down the line.
It’s also worth noting that CDTX underwent a stock split on April 24, 2024, with a factor of 1:20. Stock splits can affect share price and outstanding share count, but they don’t change the overall value of an investor’s holding.
| Metric | Value |
|---|---|
| Payout Ratio | 0.00% |
| Trailing Dividend Rate | $0.00 |
| Trailing Dividend Yield | 0.00% |
| Last Split Date | 2024-04-24 |
| Last Split Factor | 1:20 |
Technical Analysis of CDTX Stock: Bullish but Overheated?
The current price of CDTX stock is $219.02, and the trend is undeniably bullish. The stock has been on an impressive run, surging by +118.17% in just 15 days. However, several technical indicators are flashing warning signs, suggesting that while the long-term trend is up, we should approach this momentum with a degree of caution. Let’s break down what the charts are telling us.
Trend Strength – Still Bullish
CDTX is currently trading above its key moving averages, which is a strong confirmation that the uptrend is still firmly in place. The 20-day Simple Moving Average (SMA) at $138.69 is acting as a crucial immediate dynamic support level.
What This Means for Traders:
As long as CDTX can hold above the 20-day SMA ($138.69), the bullish momentum could very well continue. However, a rapid and steep rise often pushes a stock far away from its averages, which naturally increases the risk of a sharp pullback as it seeks to revert to the mean.
Momentum Check – Time to Be Cautious
Here’s where things get interesting: the RSI (Relative Strength Index) at 97.8 is screaming a strong overbought signal. Historically, when the RSI climbs above the 70-75 threshold, we frequently observe a price pullback or consolidation before the next upward move. Simultaneously, the MACD histogram remains positive, which does confirm that the underlying upward momentum is still present.
Trading Strategy:
- Aggressive traders might consider taking partial profits off the table at these levels.
- Conservative traders would be wise to wait for the RSI to cool down, ideally below 70, before even thinking about initiating new positions.
Bollinger Bands – Testing Key Levels
CDTX is currently trading comfortably in the upper half of its Bollinger Bands, nestled between the 20-day SMA and the upper band. This positioning is generally a sign of underlying strength and continued buying interest.
Key Levels to Watch:
- Resistance: The immediate resistance level to watch is the recent high of $219.64. A decisive breakout above this point, especially on strong volume, could propel CDTX even higher.
- Support: The first critical support is the 20-day SMA at $138.69. If this level breaks, we could easily see a test of the next significant support at $31.86.
Volume Trends – Checking for Conviction
The trading volume for CDTX is currently hovering near its recent average. This provides a neutral confirmation of the current price action; it’s not showing extreme buying or selling conviction, which can sometimes accompany major price moves.
Support & Resistance – The Trading Plan
Let’s distill this into a clear action plan based on these critical levels:
- ✅ If CDTX holds above $138.69: The bullish trend is likely to continue, with the next target being $219.64.
- ⚠️ If it breaks below $138.69: Expect a potential dip towards $31.86.
- 🛑 A drop below $31.86: This could trigger a much deeper correction, potentially heading towards the 200-day SMA at $66.22.
Final Verdict – Should You Buy, Hold, or Sell CDTX Stock?
Short-Term Traders:
Exercise caution! The RSI is significantly overbought at 97.8, and volume isn’t showing overwhelming conviction. It might be prudent to consider locking in some partial profits near $219.64 and then waiting for a more favorable entry point closer to the 20-day SMA (around $138.69).
Long-Term Investors:
The long-term uptrend for CDTX remains valid as long as the price stays above the crucial 200-day SMA ($66.22). A pullback into the area of the 50-day SMA ($117.16) could present a safer, more attractive buying opportunity for building a long-term position.
New Buyers:
It’s generally advised to avoid chasing this rally at its current elevated levels. Instead, wait for either a confirmed breakout above $219.64 with strong, convincing volume, or a more sensible pullback to the $138.69 area, which would offer a significantly better risk/reward entry.
Bottom Line:
The technical indicators suggest that the current rally in CDTX might be losing some steam in the short term. While the overarching long-term trend remains bullish, a healthy correction or period of consolidation seems plausible before the next significant move. Trade wisely and patiently await clear confirmations at these key technical levels.
(Please note: Images for Bollinger Bands, RSI, MACD Charts, and Historical Price & Volume are typically included in the original report. For this text-based rewrite, we describe their implications.)
CDTX Historical Performance: A Look Back
Examining the recent trading history of Cidara Therapeutics (CDTX) provides valuable context for its current market position. Over the last 15 trading days, specifically from November 05, 2025, to November 19, 2025, CDTX delivered an impressive return of +124.31%. This period saw the stock trading within a range of $95.73 to $219.64, with an average daily volume of 4,735,953 shares. Such robust performance over a short period certainly catches the eye of investors.
Recent Trading Data for CDTX Stock
Here’s a detailed look at the daily trading activity for Cidara Therapeutics (CDTX) over the last 15 trading days:
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| 2025-11-19 | $218.35 | $219.64 | $218.35 | $219.02 | 4,128,400 |
| 2025-11-18 | $218.00 | $218.84 | $217.76 | $218.41 | 2,335,800 |
| 2025-11-17 | $217.41 | $218.77 | $217.41 | $217.91 | 5,488,900 |
| 2025-11-16 | $217.20 | $218.85 | $216.80 | $217.71 | 17,289,000 |
| 2025-11-15 | $217.20 | $218.85 | $216.80 | $217.71 | 17,289,000 |
| 2025-11-14 | $217.20 | $218.85 | $216.80 | $217.71 | 17,289,000 |
| 2025-11-13 | $106.15 | $107.02 | $102.46 | $105.99 | 654,600 |
| 2025-11-12 | $108.28 | $111.27 | $105.34 | $107.12 | 574,000 |
| 2025-11-11 | $104.57 | $108.33 | $102.14 | $108.19 | 626,500 |
| 2025-11-10 | $103.24 | $106.95 | $101.39 | $103.79 | 849,200 |
| 2025-11-09 | $98.29 | $105.00 | $95.87 | $104.39 | 955,000 |
| 2025-11-08 | $98.29 | $105.00 | $95.87 | $104.39 | 955,000 |
| 2025-11-07 | $98.29 | $105.00 | $95.87 | $104.39 | 955,000 |
| 2025-11-06 | $96.70 | $101.43 | $95.73 | $98.64 | 945,000 |
| 2025-11-05 | $100.33 | $101.00 | $96.85 | $97.64 | 704,900 |
CDTX Stock Price Statistics & Volatility
When we analyze the price range for Cidara Therapeutics (CDTX) over the past year, we see a striking span, with a high of $219.64 and a low of $15.22. This wide fluctuation clearly indicates that the stock has been highly sensitive to market sentiment and company-specific news. For investors, this means CDTX can offer significant upside but also carries considerable risk.
Currently, the 50-day moving average sits at $101.82, which is comfortably above the 200-day moving average of $52.03. This configuration is often referred to as a “golden cross,” and it’s widely regarded as a bullish signal, pointing towards positive long-term momentum. It suggests that the stock’s recent performance is strong enough to pull its shorter-term average above its longer-term average.
Furthermore, CDTX carries a Beta of 1.55x. This means the stock tends to move more sharply than the broader market—specifically, about 55% more volatile than the market itself. Combine this with a very high 30-day annualized volatility of 313.7%, and it becomes clear that CDTX is a stock that experiences frequent and significant price swings. For investors, this implies both a greater potential for substantial gains and, critically, a higher downside risk. These indicators are vital when you’re deciding on position sizing or the optimal timing for entry, especially if you’re building a portfolio that aims to balance stability with growth exposure.
| Metric | Value |
|---|---|
| 52 Week High | $219.64 |
| 52 Week Low | $15.22 |
| 50 Day MA | $101.82 |
| 200 Day MA | $52.03 |
| Beta | 1.55x |
| Volatility (30d Ann.) | 313.7% |
CDTX Quarterly Earnings Performance
Let’s take a closer look at Cidara Therapeutics’ (CDTX) recent financial reporting to understand its operational health. The company’s latest quarter showed revenue of $0 and a net income of -$83.23 million. This indicates that CDTX is currently in a development phase where significant revenue generation hasn’t yet begun, and it is investing heavily, leading to a net loss.
The quarter-over-quarter and year-over-year revenue changes are currently unavailable, which further underscores that the company’s financial performance is not yet driven by product sales. This is a common characteristic of biotechnology firms focused on research and clinical trials rather than commercialization.
Recent Quarterly Results (Last 4 Quarters)
Here’s a breakdown of Cidara Therapeutics’ performance over the past four quarters:
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025-Q3 | 0 | -$83.23 Million | -3.10x |
| 2025-Q2 | 0 | -$25.72 Million | -1.65x |
| 2025-Q1 | 0 | -$23.48 Million | -1.66x |
| 2024-Q4 | 0 | -$52.31 Million | -5.37x |
CDTX Growth Metrics & Upcoming Earnings
While Cidara Therapeutics (CDTX) is in a development phase with no current revenue, we can still look at other growth indicators. The company reported a significant quarter-over-quarter net income growth of +223.6%. This dramatic increase, while still from a negative base, suggests some improvement in managing losses or timing of expenses.
Investors should mark their calendars for the next earnings report, scheduled for November 07, 2025. The earnings call will also take place on November 07, 2025, at 03:30 AM ET. These events will be crucial for understanding the company’s progress and financial outlook.
| Metric | Value |
|---|---|
| QoQ Net Income Growth | +223.6% |
| Next Report | November 07, 2025 |
| Earnings Call | November 07, 2025 at 03:30 AM ET |
CDTX Short Selling Information: Bearish Bets
Understanding short interest can give us a glimpse into how skeptical some market participants are about a stock’s future. For Cidara Therapeutics (CDTX), there’s currently about $3 million worth of short interest. The short ratio, or “days to cover,” stands at 3.2x. This means that, at CDTX’s recent average trading volume, it would take roughly 3 days for all short positions to be covered. This moderate level suggests a balance: there are bearish bets, but the market can absorb them without extreme volatility.
However, with 10.93% of the public float sold short, a significant portion of the available shares are being bet against. This signals a notable bearish conviction from a segment of the market. This percentage has remained relatively stable compared to the prior month, suggesting that bearish sentiment hasn’t dramatically shifted. For investors, high short interest implies potential volatility spikes, especially if positive news forces short sellers to quickly cover their positions, leading to a “short squeeze.”
| Metric | Value |
|---|---|
| Shares Short | 3 Million |
| Short Ratio (Days To Cover) | 3.20x |
| Short % of Float | 10.93% |
| Shares Short (Prior Month) | 3 Million |
| Short Date | 2025-10-31 |
CDTX Risk Analysis: Understanding the Swings
Investing in biotechnology stocks like Cidara Therapeutics (CDTX) often comes with a higher degree of risk, and CDTX’s profile certainly confirms this. The stock exhibits high volatility, with an annualized volatility of 76.2%. This indicates that its price can swing significantly, making it a more dynamic, but also potentially more challenging, investment.
The Sharpe ratio of 0.28x suggests mixed risk-adjusted returns. A Sharpe ratio measures the return of an investment compared to its risk, showing how much excess return you receive for the volatility you endure. A low positive number like this indicates that while there are returns, they might not be fully compensating for the risk taken.
A significant concern is the maximum drawdown of -97.52%, which highlights the substantial downside risk the stock has experienced during adverse market conditions. This means that at some point, the stock has fallen nearly entirely from its peak, a stark reminder of the potential for capital loss.
To further quantify risk, the Value at Risk (VaR) at a 5% confidence level shows a potential loss of -5.66%. This means that in the worst 5% of scenarios, an investor could theoretically lose at least 5.66% of their investment over a given period. The Sortino ratio of 0.48x, which specifically focuses on downside risk, provides additional insight into risk-adjusted performance by penalizing only negative volatility.
Investors absolutely must consider these risk metrics in conjunction with their own risk tolerance and investment objectives. CDTX is clearly not for the faint of heart.
| Metric | Value |
|---|---|
| Volatility (Annualized) | 76.2% |
| Value at Risk (5%) | -5.66% |
| Value at Risk (1%) | -8.90% |
| Sharpe Ratio | 0.28x |
| Sortino Ratio | 0.48x |
| Maximum Drawdown | -97.52% |
| Skewness | 6.88x |
| Kurtosis | 157.53x |
CDTX Sentiment Analysis: A Cautiously Positive Outlook
The current market sentiment surrounding Cidara Therapeutics (CDTX) appears cautiously positive, based on a composite sentiment score of 0.19x with a confidence level of 45.7%. This “positive” classification, while not overwhelmingly strong, is derived from a variety of data sources, including recent news coverage, analyst recommendations, and activity in the options market.
Let’s break down these sentiment components further:
- News analysis shows a Positive sentiment score of 0.12x.
- Analyst consensus leans Neutral, with a score of 0.00x.
- Options market sentiment reflects a more robust Positive outlook, coming in at 0.61x, suggesting that options traders are leaning bullish.
Despite the overall “Positive” classification, it’s important to recognize that this is considered a “weak sentiment signal” due to the relatively low confidence level. Therefore, investors should always consider this sentiment alongside a thorough fundamental and technical analysis for a truly comprehensive investment perspective. It’s a piece of the puzzle, not the whole picture.
| Metric | Value |
|---|---|
| Composite Sentiment Score | 0.19x |
| Sentiment Classification | Positive |
| Sentiment Confidence | 45.7% |
| News Sentiment | Positive (0.12x) |
| Analyst Sentiment | Neutral (0.00x) |
| Options Sentiment | Positive (0.61x) |
| Put/Call Ratio | 0.20x |
CDTX Peer Comparison: How Does Cidara Stack Up?
To truly understand Cidara Therapeutics (CDTX), it’s essential to see how it compares to its industry rivals. With a market capitalization of $6.89 billion, CDTX is positioned as the smallest among its close peers, which include HALO ($8.26B), CYTK ($7.92B), and NUVL ($7.79B).
When we look at profitability, CDTX currently presents negative earnings, making a traditional P/E ratio analysis challenging. In contrast, HALO trades at a P/E of 14.82x, while CYTK and NUVL also show negative P/E ratios (-12.02x and -25.27x respectively) due to current losses. This highlights that many companies in this biotech space are still in growth or development phases rather than consistently profitable.
CDTX faces significant profitability challenges, reflected in its 0.0% net margin, which is considerably lower than HALO’s impressive 47.91%. Similarly, CDTX’s negative -68.70% ROE underscores its current unprofitability. However, its conservative 0.47x debt-to-equity ratio suggests a relatively strong balance sheet, especially when compared to HALO’s much higher leverage at 305x.
| Metric | CDTX | HALO | CYTK | NUVL |
|---|---|---|---|---|
| Market Cap | $6.89B | $8.26B | $7.92B | $7.79B |
| P/E Ratio | -28.04 | 14.82 | -12.02 | -25.27 |
| Revenue Growth | N/A | 22.10% | 3.18% | N/A |
| Net Margin | 0.00% | 47.91% | 0.00% | 0.00% |
| EPS | -11.21 | 4.74 | -6.30 | -5.33 |
| ROE | -68.70% | 1.24% | N/A | -38.79% |
| Debt-to-Equity | 0.47 | 305 | N/A | N/A |
| Dividend Yield | 0.00% | 0.00% | 0.00% | 0.00% |
| 52-Week Range | 15.02 – 219.64 | 44.10 – 79.50 | 29.31 – 67.98 | 55.53 – 112.53 |
Insider Transactions for CDTX (Last 3 Months)
Insider activity can sometimes offer a fascinating glimpse into how those closest to the company view its prospects. Over the last three months, Cidara Therapeutics (CDTX) saw a total of 31 insider transactions. What’s crucial to note is that a significant majority of these (25 transactions) were stock awards or tax-related dispositions. These types of transactions are typically routine equity compensation and aren’t usually a strong directional signal about the company’s future.
In terms of actual market transactions, there were 28 buys and only 3 sells. While the number of buys outweighs sells, it’s important to differentiate between awards (non-cash events) and actual market purchases. Only 26% of transactions had price data available, meaning many were non-market activities. The predominance of award-related transactions suggests that this activity largely reflects standard employee and executive compensation rather than insiders making aggressive market bets.
| Insider Name | Type | Shares Changed | Price | Shares After | Transaction Date | Filing Date |
|---|---|---|---|---|---|---|
| Davarpanah Nicole Negar | SELL (Sale) | -474 | $62.86 | 31,418 | 2025-09-11 | 2025-09-15 |
| RA Capital Healthcare Fund LP | BUY (Purchase) | +2,272,727 | $44.00 | 3,365,523 | 2025-06-26 | 2025-06-30 |
| Resnick Joshua | BUY (Award) | +5,079 | N/A (Stock award/grant (typically no cash price)) | 5,079 | 2025-06-18 | 2025-06-18 |
| Spencer Ryan | BUY (Award) | +11,100 | N/A (Stock award/grant (typically no cash price)) | 11,100 | 2025-06-18 | 2025-06-18 |
| Merson James | BUY (Award) | +11,100 | N/A (Stock award/grant (typically no cash price)) | 11,100 | 2025-06-18 | 2025-06-18 |
| Canale-Theakston Carin | BUY (Award) | +11,100 | N/A (Stock award/grant (typically no cash price)) | 11,100 | 2025-06-18 | 2025-06-18 |
| Bassler Bonnie L | BUY (Award) | +11,100 | N/A (Stock award/grant (typically no cash price)) | 11,100 | 2025-06-18 | 2025-06-18 |
| Mineo Chrysa | BUY (Award) | +11,100 | N/A (Stock award/grant (typically no cash price)) | 11,100 | 2025-06-18 | 2025-06-18 |
| Schroeder Theodore R | BUY (Award) | +11,100 | N/A (Stock award/grant (typically no cash price)) | 11,100 | 2025-06-18 | 2025-06-18 |
| RA Capital Healthcare Fund LP | BUY (Award) | +5,079 | N/A (Stock award/grant (typically no cash price)) | 5,079 | 2025-06-18 | 2025-06-18 |
| BURGESS DANIEL D | BUY (Award) | +11,100 | N/A (Stock award/grant (typically no cash price)) | 11,100 | 2025-06-18 | 2025-06-18 |
| Mineo Chrysa | BUY (Purchase) | +1,050 | $23.44 | 3,320 | 2025-06-03 | 2025-06-04 |
| Mineo Chrysa | BUY (Purchase) | +2,270 | $21.71 | 2,270 | 2025-06-02 | 2025-06-04 |
| Davarpanah Nicole Negar | BUY (Award) | +20,000 | N/A (Stock award/grant (typically no cash price)) | 20,000 | 2025-05-01 | 2025-05-12 |
| Davarpanah Nicole Negar | BUY (Award) | +10,000 | N/A (Stock award/grant (typically no cash price)) | 31,692 | 2025-05-01 | 2025-05-12 |
| Ward Shane | BUY (Award) | +50,000 | N/A (Stock award/grant (typically no cash price)) | 50,000 | 2025-03-31 | 2025-04-02 |
| Ward Shane | BUY (Award) | +25,000 | N/A (Stock award/grant (typically no cash price)) | 39,674 | 2025-03-31 | 2025-04-02 |
| Stein Jeffrey | BUY (Award) | +275,000 | N/A (Stock award/grant (typically no cash price)) | 275,000 | 2025-03-31 | 2025-04-02 |
| Ward Shane | SELL (Sale) | -1,664 | $21.96 | 14,674 | 2025-03-11 | 2025-03-13 |
| Tari Leslie | SELL (Sale) | -1,773 | $21.96 | 16,215 | 2025-03-11 | 2025-03-13 |
| KARBE FRANK | BUY (Award) | +115,000 | N/A (Stock award/grant (typically no cash price)) | 115,000 | 2025-02-24 | 2025-02-26 |
| KARBE FRANK | BUY (Award) | +57,500 | N/A (Stock award/grant (typically no cash price)) | 57,500 | 2025-02-24 | 2025-02-26 |
| Resnick Joshua | BUY (Award) | +22,200 | N/A (Stock award/grant (typically no cash price)) | 22,200 | 2025-01-03 | 2025-01-07 |
| RA Capital Healthcare Fund LP | BUY (Award) | +22,200 | N/A (Stock award/grant (typically no cash price)) | 22,200 | 2025-01-03 | 2025-01-07 |
| Bassler Bonnie L | BUY (Award) | +16,000 | N/A (Stock award/grant (typically no cash price)) | 16,000 | 2024-12-17 | 2024-12-19 |
| Canale-Theakston Carin | BUY (Award) | +16,000 | N/A (Stock award/grant (typically no cash price)) | 16,000 | 2024-12-17 | 2024-12-19 |
| Mineo Chrysa | BUY (Award) | +19,000 | N/A (Stock award/grant (typically no cash price)) | 19,000 | 2024-12-17 | 2024-12-19 |
| Schroeder Theodore R | BUY (Award) | +20,500 | N/A (Stock award/grant (typically no cash price)) | 20,500 | 2024-12-17 | 2024-12-19 |
| BURGESS DANIEL D | BUY (Award) | +20,500 | N/A (Stock award/grant (typically no cash price)) | 20,500 | 2024-12-17 | 2024-12-19 |
| RA Capital Healthcare Fund LP | BUY (Award) | +1,286,786 | $14.91 | 1,286,786 | 2024-11-26 | 2024-11-29 |
| RA Capital Healthcare Fund LP | BUY (Award) | +389,716 | $14.91 | 1,092,796 | 2024-11-26 | 2024-11-29 |
Risk Factors for Investing in CDTX Stock
Any potential investor considering Cidara Therapeutics (CDTX) should be fully aware of the inherent risks. While this list highlights key considerations based on available data and market dynamics, it’s not exhaustive. Always conduct your own thorough research.
- ⚠️ The RSI (Relative Strength Index) is extremely high at 97.8. This suggests that the stock is currently in an overbought condition, which often precedes a price pullback or consolidation.
- ⚠️ General market fluctuations and broader economic conditions can significantly impact stocks within the Healthcare sector, including CDTX. Biotech companies can be particularly sensitive to changes in investor sentiment and economic outlook.
- ⚠️ As discussed in the Peer Comparison, CDTX faces intense competition from both established pharmaceutical companies and other innovative biotech firms. This competitive landscape could impact future market share and profitability.
- ⚠️ Cidara Therapeutics is currently in a development phase with negative profitability and cash flow. Its future success heavily relies on successful clinical trials, regulatory approvals, and eventual commercialization of its products, which are all inherently risky processes.
- ⚠️ The company carries debt, and while manageable currently, any increase in interest rates could put pressure on its financial health, especially given its negative operating cash flow.
CDTX Analyst Insights and Consensus
It’s always helpful to gauge the collective wisdom of Wall Street professionals who closely follow a company. For Cidara Therapeutics (CDTX), the consensus recommendation from analysts is currently a ‘Hold’. This view is based on the opinions of 4 analysts covering the stock.
The mean price target set by these analysts is $209.38. Individual price targets range from a low of $173.00 to a high of $221.50. What’s important to note is that this mean target of $209.38 implies a potential downside of approximately -4.4% from the current price of $219.02. This provides a clear indication of Wall Street’s sentiment regarding the stock’s potential movement in the near to medium term.
| Metric | Value |
|---|---|
| Recommendation | Hold |
| Mean Target Price | $209.38 |
| High Target Price | $221.50 |
| Low Target Price | $173.00 |
| Number of Analyst Opinions | 4 |
Recent News and Developments for Cidara Therapeutics (CDTX)
Staying updated with the latest news is crucial for any investor. Here are some recent headlines concerning Cidara Therapeutics (CDTX) and the broader biotechnology sector that could influence its stock performance:
- PFE- The Winner in the Metsera Bidding War (Publisher: MoneyShow, Published: 2025-11-19T05:01:00Z)
- Merck Writes a $9.2 Billion Check for a Flu Drug That Could Change Everything (Publisher: MarketBeat, Published: 2025-11-18T19:22:00Z)
- Merck Stock Rises as Heart-Drug Test Offers Hope for Post-Keytruda Era (Publisher: Barrons.com, Published: 2025-11-18T15:26:00Z)
- Is Cidara Therapeutics Fairly Priced After Its 110% Surge and New Clinical Milestones? (Publisher: Simply Wall St., Published: 2025-11-18T07:11:02Z)
- Sector Update: Health Care Stocks Softer Late Afternoon (Publisher: MT Newswires, Published: 2025-11-17T20:57:57Z)
These articles highlight both specific company developments and broader industry trends that can impact CDTX.
Conclusion and Outlook for CDTX Stock
So, where does this leave us with Cidara Therapeutics (CDTX) stock? It’s clear that CDTX presents a compelling, albeit complex, investment case. Let’s summarize the key takeaways.
Short-Term Technical Snapshot
- ▲ Overall Technical Sentiment: Currently, it’s looking “Strong Bullish.”
- ▲ Price Trend vs MAs: The stock is bullish, trading comfortably above both its 50-day and 200-day Simple Moving Averages.
- ⚠️ Momentum (RSI): A significant warning here – the RSI is flashing “Overbought” at 97.8, suggesting a potential pullback is due.
- 📊 Support / Resistance (30d): Key levels to watch are approximately $93.00 for support and $219.64 for resistance.
Longer-Term Fundamental & Forecast Outlook
- ▲ 1-Year Avg. Forecast: Models project a potential upside of approximately +32.9%, targeting around $291.09.
- ● Fundamental Health: The assessment is currently incomplete due to negative profitability (ROE: -68.70%), though its Debt/Equity ratio (0.47x) indicates manageable debt.
- ● Valuation Snapshot: Appears “Moderate” based on a Forward P/E of -28.04x, reflecting its current development stage.
- ● Recent Growth (YoY): Revenue and earnings growth are currently unavailable, as the company is not yet generating significant sales.
- ● Analyst Consensus: Analysts generally recommend a “Hold” with a mean target of $209.38.
Overall Assessment & Outlook
In summary, CDTX offers a technical picture that screams “Strong Bullish” momentum, yet this is tempered by fundamental health that’s still evolving. The current valuation, while appearing moderate, needs to be understood in the context of a biotech company heavily investing in its future. Our models project a promising 1-year path, indicating potential upside of +32.9%, with a target around $291.09.
However, don’t forget the caveats. The extremely high RSI suggests a short-term correction is plausible. Cidara Therapeutics is a company with significant potential in the biotechnology space, but it also carries the inherent risks of a development-stage firm. Investors must carefully consider these points against the outlined risk factors and their own strategic investment goals. It’s a stock that demands active monitoring and a clear understanding of its unique position.
Pingback: D-Wave Quantum Inc. (QBTS) Stock Analysis, Price Prediction, Forecast 2025 - Stockdunia
Pingback: Ondas Holdings Inc. (ONDS) Stock Analysis - Stockdunia